Status:
COMPLETED
Study of Sugammadex Versus Usual Care on Incidence of Residual Blockade at Post Anesthesia Care Unit Admission (P07981)
Lead Sponsor:
Merck Sharp & Dohme LLC
Conditions:
Surgical Procedures, Elective
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
This study will compare the incidence of residual neuromuscular blockade in participants who undergo reversal of neuromuscular blockade with sugammadex compared to those who undergo reversal of neurom...
Eligibility Criteria
Inclusion
- American Society of Anesthesiologists (ASA) Class 1 or 2 or 3
- Scheduled to undergo an elective abdominal surgical procedure under general anesthesia; and:
- expected to undergo neuromuscular relaxation with rocuronium for
- endotracheal intubation; and
- expected to require at least one maintenance dose of rocuronium; and
- expected to require active reversal of neuromuscular blockade; and
- expected to require clinical or subjective neuromuscular monitoring only; and
- expected to recover in the PACU
- Arm that is accessible for measuring the TOF ratio in the PACU
- Sexually active female patient of child-bearing potential must agree to use a
- medically accepted method of contraception through seven days after receiving
- protocol-specified medication.
Exclusion
- Anatomical malformations that may lead to difficult intubation
- Neuromuscular disorder(s) that may affect neuromuscular blockade and/or trial assessments
- Dialysis-dependent or has or is suspected of having severe renal insufficiency
- Significant hepatic dysfunction
- Family history of malignant hyperthermia
- Cardiac pacemaker
- Allergy to study treatments or its/their excipients, to opioids / opiates, sugammadex, muscle relaxants or their excipients, or other medication(s) used during general anesthesia
- Toremifene before or within 24 hours of study drug administration
- Scheduled for an overnight stay (or \>12 hours) in PACU
- Expected transfer to an Intensive Care Unit after surgery
- Pregnant, intention to become pregnant between randomization and the Day 30 pregnancy follow-up visit
- Breast-feeding.
- Investigational drug(s) within 30 days of randomization on this study
- Participation in any other clinical trial within 30 days, inclusive, of signing the informed consent form of the current trial
- Participant or family member is among the personnel of the investigational or Sponsor staff directly involved with this trial
Key Trial Info
Start Date :
December 2 2011
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 5 2012
Estimated Enrollment :
154 Patients enrolled
Trial Details
Trial ID
NCT01479764
Start Date
December 2 2011
End Date
November 5 2012
Last Update
June 6 2017
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.